Does Security Health Plan Cover Eliquis?

How Security Health Plan Typically Covers Eliquis

Security Health Plan, based in Marshfield, Wisconsin, operates as a regional insurer offering HMO, POS, and Medicare Advantage products across central and northern Wisconsin. The plan maintains a multi-tier formulary that classifies drugs by cost and clinical preference. Eliquis appears on most Security Health Plan formularies as a brand-name anticoagulant, though the specific tier varies by product line.

Formulary Tier Placement

Most commercial Security Health Plan products place Eliquis on Tier 3 (preferred brand) or Tier 4 (non-preferred brand). Tier 3 copays for brand drugs on regional Wisconsin plans typically range from $35 to $60 per 30-day supply, while Tier 4 placement can push costs to $70 to $90 [1]. Medicare Advantage formularies through Security Health Plan may assign different cost-sharing, often with a coverage gap ("donut hole") phase where out-of-pocket spending rises significantly.

Prior Authorization and Step Therapy

Some Security Health Plan products require prior authorization for Eliquis, particularly when prescribed for indications beyond atrial fibrillation. Step therapy protocols may mandate a documented trial of warfarin before approving a DOAC. The American College of Cardiology and American Heart Association 2019 guidelines on atrial fibrillation management recommend DOACs over warfarin for most patients with non-valvular AF, stating that "DOACs are recommended in preference to warfarin... Except in patients with moderate-to-severe mitral stenosis or a mechanical heart valve" [2]. This guideline language can support a prior authorization appeal if step therapy is imposed.

How to Verify Your Specific Coverage

Call the member services number on the back of your Security Health Plan ID card. Ask three questions: Is apixaban (Eliquis) on my formulary? What tier? Does my plan require prior authorization or step therapy? You can also search Security Health Plan's online formulary tool by entering "apixaban" or the NDC number (specific packaging codes vary by dose strength).

Why Eliquis Is Widely Prescribed

Eliquis belongs to the direct oral anticoagulant (DOAC) class, which has largely replaced warfarin as first-line anticoagulation for atrial fibrillation and venous thromboembolism. The drug inhibits Factor Xa, a clotting protein, and does not require routine INR monitoring. That convenience matters. Warfarin demands regular blood draws, dietary restrictions on vitamin K intake, and frequent dose adjustments.

Clinical Trial Evidence

The ARISTOTLE trial (N=18,201) compared apixaban 5 mg twice daily to warfarin in patients with atrial fibrillation and at least one stroke risk factor. Apixaban reduced the rate of stroke or systemic embolism by 21% compared to warfarin (1.27% vs. 1.60% per year, P<0.001 for non-inferiority, P=0.01 for superiority) [3]. Major bleeding occurred in 2.13% of apixaban-treated patients per year versus 3.09% with warfarin, a 31% relative reduction [3].

Real-World Bleeding Outcomes

The ARISTOPHANES study, a large retrospective analysis of over 285,000 patients using U.S. Claims data, confirmed lower rates of stroke and major bleeding with apixaban compared to rivaroxaban, dabigatran, and warfarin in routine clinical practice [4]. Dr. Alexander Cohen, professor of vascular medicine at King's College London, noted in commentary on real-world DOAC data that "the consistency between trial results and observational studies strengthens confidence in apixaban's safety profile across diverse patient populations" [5].

What Eliquis Costs Without Full Insurance Coverage

Without insurance, a 30-day supply of Eliquis 5 mg twice daily costs approximately $550 to $600 at major U.S. Retail pharmacies [6]. That translates to roughly $6,600 to $7,200 annually. Even with Security Health Plan coverage, the brand copay can strain budgets. Several strategies can reduce out-of-pocket spending.

Bristol-Myers Squibb / Pfizer Copay Card

Commercially insured patients (not Medicare, Medicaid, or other government programs) can enroll in the Eliquis copay assistance program, which may reduce the monthly copay to as low as $10 for eligible patients, with a maximum annual benefit [6]. This program stacks on top of Security Health Plan coverage and applies at the pharmacy counter automatically once activated.

Patient Assistance Programs

Uninsured or underinsured patients may qualify for Bristol-Myers Squibb's Patient Assistance Foundation, which provides Eliquis at no cost to eligible individuals below certain income thresholds. Household income limits typically fall at or below 300% of the federal poverty level [6].

Medicare Advantage Considerations

Security Health Plan's Medicare Advantage products follow CMS formulary rules. In 2025, the Inflation Reduction Act capped Medicare Part D out-of-pocket drug costs at $2,000 annually, which meaningfully changes the calculus for high-cost brand drugs like Eliquis [7]. Patients who previously paid $3,000 or more in the coverage gap phase now benefit from this hard cap. If your Security Health Plan Medicare Advantage enrollment predates this provision, confirm that the $2,000 cap is reflected in your current benefit summary.

Prior Authorization: How to Manage an Approval

When Security Health Plan requires prior authorization for Eliquis, the prescribing physician's office submits clinical documentation to justify medical necessity. Approval turnaround times typically range from 24 to 72 hours for standard requests. Urgent requests (e.g., hospital discharge with new AF diagnosis) can be expedited to within 24 hours.

What Documentation Strengthens an Approval

A strong prior authorization request includes the patient's CHA₂DS₂-VASc score (stroke risk), HAS-BLED score (bleeding risk), documented contraindication or intolerance to warfarin if step therapy applies, and the specific FDA-approved indication. The 2023 AHA/ACC/ACCP/HRS guideline update reaffirmed that "for patients with AF and a CHA₂DS₂-VASc score of 2 or greater in men or 3 or greater in women, oral anticoagulation is recommended" [8].

What to Do If Denied

If Security Health Plan denies coverage, you have the right to appeal. Request the denial in writing, including the specific formulary exclusion or clinical rationale cited. Your physician can submit a letter of medical necessity citing guideline recommendations and individual patient factors. External review through Wisconsin's Office of the Commissioner of Insurance is available if internal appeals are exhausted.

Timeline for Appeals

Internal appeals at Security Health Plan typically receive a decision within 30 days for non-urgent cases. Expedited appeals for active treatment needs are resolved within 72 hours. Keep copies of all submitted documentation.

Eliquis vs. Other Anticoagulants Covered by Security Health Plan

Security Health Plan formularies typically list multiple anticoagulants across different tiers. Understanding tier placement for alternatives helps when comparing cost and clinical fit.

Warfarin

Warfarin (generic) usually sits on Tier 1, with copays as low as $0 to $10. It remains effective but carries a narrower therapeutic window, requires INR monitoring every 1 to 4 weeks, and interacts extensively with foods and other medications [9]. For patients without access barriers or monitoring challenges, warfarin remains an evidence-based option. The RE-LY, ROCKET-AF, and ARISTOTLE trials collectively enrolled over 50,000 patients and showed DOACs as a class to be non-inferior or superior to warfarin for stroke prevention with equal or lower bleeding risk [3][10][11].

Rivaroxaban (Xarelto)

Rivaroxaban is often placed on the same tier as Eliquis (Tier 3 or 4). Once-daily dosing is an advantage for adherence, though the ROCKET-AF trial showed a numerically higher rate of GI bleeding with rivaroxaban compared to warfarin [11]. In ARISTOPHANES, apixaban had lower rates of major bleeding compared to rivaroxaban (HR 0.60, 95% CI 0.56 to 0.65) [4].

Dabigatran (Pradaxa)

Dabigatran, another DOAC, may be formulary-listed at a similar tier. The RE-LY trial (N=18,113) showed dabigatran 150 mg twice daily was superior to warfarin for stroke prevention (1.11% vs. 1.69% per year) but with higher rates of GI bleeding [10]. Dabigatran has the advantage of an approved reversal agent, idarucizumab (Praxbind), and apixaban can be reversed with andexanet alfa (Andexxa), though andexanet alfa carries its own cost and availability constraints [12].

Dosing and Monitoring While on Eliquis

Standard dosing for stroke prevention in AF is 5 mg twice daily. A reduced dose of 2.5 mg twice daily applies when patients meet at least two of three criteria: age 80 years or older, body weight 60 kg or less, or serum creatinine 1.5 mg/dL or higher [1]. Incorrect dose reduction is a recognized problem. A 2022 analysis published in the Journal of the American College of Cardiology found that 16.3% of AF patients on apixaban in clinical practice received inappropriately reduced doses, which was associated with higher stroke rates without a bleeding benefit [13].

Renal Function Monitoring

Apixaban is partially renally cleared (about 27%), and dose adjustment follows the criteria above rather than a strict creatinine clearance cutoff. Periodic renal function checks (every 6 to 12 months, or more frequently in older adults or those with declining kidney function) are recommended by the European Heart Rhythm Association [14].

Drug Interactions to Discuss With Your Provider

Strong dual inhibitors of CYP3A4 and P-glycoprotein (e.g., ketoconazole, ritonavir) increase apixaban exposure and require dose reduction. Strong dual inducers (e.g., rifampin, carbamazepine, phenytoin) decrease apixaban levels and should be avoided [1]. NSAIDs and antiplatelet agents increase bleeding risk when combined with any anticoagulant. Report all medications, including over-the-counter drugs and supplements, to your prescriber.

When to Talk to Your Doctor About Switching

Switching anticoagulants is a clinical decision, not just a cost decision. Valid reasons include persistent side effects (GI discomfort with rivaroxaban, dyspepsia with dabigatran), changes in renal function, new drug interactions, or a formulary change that makes one DOAC significantly more affordable.

Bridging and Transition Protocols

Transitioning between DOACs does not require heparin bridging in most cases. The standard approach: start the new DOAC at the time the next dose of the prior DOAC was due [14]. Switching from warfarin to apixaban requires discontinuing warfarin and starting apixaban when INR falls below 2.0. Discuss all transitions with your prescriber, not your pharmacy.

Cost-Driven Switches

If Security Health Plan moves Eliquis to a higher tier or imposes new restrictions mid-year, your prescriber can request a formulary exception to maintain the current copay level. Document clinical stability on the current regimen and cite guideline support for the chosen agent.

The Broader Picture: Anticoagulant Access in Wisconsin

Wisconsin's insurance marketplace includes Security Health Plan as a significant regional option, particularly in the Marshfield Clinic Health System network. Patients in rural counties may have limited pharmacy options, which can affect brand drug pricing. The 340B Drug Pricing Program, available at qualifying federally funded health centers and critical access hospitals in Wisconsin, can reduce Eliquis costs for eligible patients regardless of insurance status [15].

A 2023 CDC report found that atrial fibrillation affects approximately 12.1 million people in the United States, with prevalence projected to rise as the population ages [16]. Ensuring affordable access to guideline-recommended anticoagulants is a public health priority, not just an individual insurance question.

Confirm your Eliquis coverage by calling Security Health Plan at the number on your member ID card, requesting a written formulary exception if your current tier is unaffordable, and enrolling in the manufacturer copay card if you carry commercial (non-government) insurance.